{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:41:56Z","timestamp":1793148116976,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007123","name":"Stanley Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jad.2019.10.021","type":"journal-article","created":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T09:55:13Z","timestamp":1570960513000},"page":"145-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Modulation of the inflammatory response benefits treatment-resistant bipolar depression: A randomized clinical trial"],"prefix":"10.1016","volume":"261","author":[{"given":"Angelos","family":"Halaris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Cantos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hakimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Sinacore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2019.10.021_bib0001","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jad.2012.03.033","article-title":"Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study","volume":"141","author":"Abbasi","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.10.021_bib0002","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/da.20589","article-title":"Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial","volume":"26","author":"Akhondzadeh","year":"2009","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2019.10.021_bib0003","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bdi.12324","article-title":"Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial","volume":"17","author":"Arabzadeh","year":"2015","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.jad.2019.10.021_bib0004","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1600-0447.2011.01818.x","article-title":"Predominant recurrence polarity among 928 adult international bipolar I disorder patients","volume":"125","author":"Baldessarini","year":"2012","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2019.10.021_bib0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000356539","article-title":"The immunology of bipolar disorder","volume":"21","author":"Barbosa","year":"2014","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.jad.2019.10.021_bib0006","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.npbr.2019.03.005","article-title":"Celecoxib augmentation of escitalopram in treatment-resistant bipolar depression and the effects on quinolinic acid","volume":"32","author":"Castillo","year":"2019","journal-title":"Neurol. Psychiatry Brain Res."},{"key":"10.1016\/j.jad.2019.10.021_bib0007","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jad.2006.01.032","article-title":"Clinical and therapeutic implications of predominant polarity in bipolar disorder","volume":"93","author":"Colom","year":"2006","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.10.021_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2018.02.004","article-title":"Plasma C-reactive protein levels in bipolar depression during cyclooxygenase-2 inhibitor combination treatment","volume":"102","author":"Edberg","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2019.10.021_bib0009","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4088\/JCP.08m04309","article-title":"A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method","volume":"70","author":"Fekadu","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.021_bib0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pbb.2018.12.006","article-title":"Revisiting inflammation in bipolar disorder","volume":"177","author":"Fries","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.jad.2019.10.021_bib0011","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI27291","article-title":"Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities","volume":"116","author":"Grosser","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jad.2019.10.021_bib0012","unstructured":"Harvard Medical School, 2007. National Comorbidity Survey (NSC)[WWW Document]. URLhttps:\/\/www.hcp.med.harvard.edu\/ncs\/index.php(accessed 7.15.19)."},{"key":"10.1016\/j.jad.2019.10.021_bib0013","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1192\/bjp.2018.257","article-title":"Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition","volume":"214","author":"Hidalgo-Mazzei","year":"2019","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.021_bib0014","first-page":"73","article-title":"Bipolar depression: an underestimated treatment challenge. depress","volume":"5","author":"Hlastala","year":"1997","journal-title":"Anxiety"},{"key":"10.1016\/j.jad.2019.10.021_bib0015","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/1570159X13666150630171954","article-title":"Pharmacological approaches for treatment-resistant bipolar disorder","volume":"13","author":"Hui Poon","year":"2015","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.jad.2019.10.021_bib0016","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1177\/0269881117725711","article-title":"Anti-inflammatory treatments for mood disorders: systematic review and meta-analysis","volume":"31","author":"Husain","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2019.10.021_bib0017","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/archpsyc.60.3.261","article-title":"A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder","volume":"60","author":"Judd","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.021_bib0018","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","article-title":"The long-term natural history of the weekly symptomatic status of bipolar I disorder","volume":"59","author":"Judd","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.021_bib0019","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/acps.13016","article-title":"Efficacy of anti\u2010inflammatory treatment on major depressive disorder or depressive symptoms: meta\u2010analysis of clinical trials","volume":"139","author":"K\u00f6hler\u2010Forsberg","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2019.10.021_bib0020","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1399-5618.2007.00467.x","article-title":"Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder","volume":"9","author":"Kupka","year":"2007","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.jad.2019.10.021_bib0021","first-page":"891","article-title":"A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in treatment of drug-naive depressed women: a pilot study","volume":"14","author":"Majd","year":"2015","journal-title":"Iran. J. Pharm. Res. IJPR"},{"key":"10.1016\/j.jad.2019.10.021_bib0022","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00004850-200607000-00005","article-title":"Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study","volume":"21","author":"Mendlewicz","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2019.10.021_bib0023","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1089\/cap.2016.0207","article-title":"A randomized, double-blind placebo-controlled trial on effectiveness and safety of celecoxib adjunctive therapy in adolescents with acute bipolar mania","volume":"27","author":"Mousavi","year":"2017","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.jad.2019.10.021_bib0024","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3389\/fpsyt.2019.00375","article-title":"COX-2 inhibitors, aspirin, and other potential anti-inflammatory treatments for psychiatric disorders","volume":"10","author":"M\u00fcller","year":"2019","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.021_bib0025","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/sj.mp.4001805","article-title":"The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine","volume":"11","author":"M\u00fcller","year":"2006","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.021_bib0026","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.npbr.2019.07.001","article-title":"Effects of inflammation modulation on tryptophan and kynurenine pathway regulation in treatment resistant bipolar depression","volume":"33","author":"Murata","year":"2019","journal-title":"Neurol. Psychiatry Brain Res."},{"key":"10.1016\/j.jad.2019.10.021_bib0027","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pnpbp.2013.09.006","article-title":"Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis","volume":"48","author":"Na","year":"2014","journal-title":"Prog. Neuro-Psychopharmacology Biol. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.021_bib0028","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hup.912","article-title":"Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study","volume":"23","author":"Nery","year":"2008","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.jad.2019.10.021_bib0029","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","article-title":"Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis","volume":"375","author":"Nissen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2019.10.021_bib0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jad.2005.11.015","article-title":"Cytokine profiles in bipolar affective disorder: focus on acutely ill patients","volume":"90","author":"O'Brien","year":"2006","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2019.10.021_bib0031","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1399-5618.2007.00493.x","article-title":"Immune variations in bipolar disorder: phasic differences","volume":"9","author":"Ortiz-Dom\u00ednguez","year":"2007","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.jad.2019.10.021_bib0032","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.4088\/JCP.v64n1108","article-title":"Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs","volume":"64","author":"Phelan","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.021_bib0033","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s11136-005-2816-9","article-title":"Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective,and mood disorder patients","volume":"14","author":"Ritsner","year":"2005","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.jad.2019.10.021_bib0034","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1524-4733.2010.00768.x","article-title":"Functional impairment and disability across mood states in bipolar disorder","volume":"13","author":"Rosa","year":"2010","journal-title":"Value Heal"},{"key":"10.1016\/j.jad.2019.10.021_bib0035","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/brainsci7110144","article-title":"Bipolar disorder and immune dysfunction: epidemiological findings, proposed pathophysiology and clinical implications","volume":"7","author":"Rosenblat","year":"2017","journal-title":"Brain Sci."},{"key":"10.1016\/j.jad.2019.10.021_bib0036","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bdi.12108","article-title":"Aspirin for treatment of lithium-associated sexual dysfunction in men: randomized double-blind placebo-controlled study","volume":"15","author":"Saroukhani","year":"2013","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.jad.2019.10.021_bib0037","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41398-017-0073-7","article-title":"Treatment of bipolar depression with minocycline and\/or aspirin: an adaptive, 2\u202f\u00d7\u202f2 double-blind, randomized, placebo-controlled, phase IIA clinical trial","volume":"8","author":"Savitz","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.021_bib0038","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.4088\/JCP.v68n0811","article-title":"Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression","volume":"68","author":"Simon","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2019.10.021_bib0039","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1007\/s12035-016-0124-8","article-title":"Associations of serum cytokine receptor levels with melancholia, staging of illness, depressive and manic phases, and severity of depression in bipolar disorder","volume":"54","author":"Siwek","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jad.2019.10.021_bib0040","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.amjmed.2017.06.028","article-title":"The risk of major nsaid toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the precision trial","volume":"130","author":"Solomon","year":"2017","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jad.2019.10.021_bib0041","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11920-013-0431-y","article-title":"Options for pharmacological treatment of refractory bipolar depression","volume":"16","author":"Tondo","year":"2014","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.jad.2019.10.021_bib0042","unstructured":"U.S. Food & Drug Administration, 2018. CDER statement: fda approves labeling supplement for celebrex (celecoxib) | FDA [WWW document]. URLhttps:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/cder-statement-fda-approves-labeling-supplement-celebrex-celecoxib(accessed 6.28.19)."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032719321809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032719321809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:29:33Z","timestamp":1759022973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032719321809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":42,"alternative-id":["S0165032719321809"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2019.10.021","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modulation of the inflammatory response benefits treatment-resistant bipolar depression: A randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2019.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}